scispace - formally typeset
V

Vahid Salimi

Researcher at Tehran University of Medical Sciences

Publications -  96
Citations -  3174

Vahid Salimi is an academic researcher from Tehran University of Medical Sciences. The author has contributed to research in topics: Medicine & Virus. The author has an hindex of 17, co-authored 70 publications receiving 1909 citations. Previous affiliations of Vahid Salimi include Utrecht University.

Papers
More filters
Journal ArticleDOI

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study

Ting Shi, +138 more
- 02 Sep 2017 - 
TL;DR: In this paper, the authors estimated the incidence and hospital admission rate of RSV-associated acute lower respiratory infection (RSV-ALRI) in children younger than 5 years stratified by age and World Bank income regions.
Journal ArticleDOI

Anti-inflammatory MicroRNAs and their potential for inflammatory diseases treatment

TL;DR: Recent findings related to significant roles of miRNAs in immune regulation, especially the potential utility of these molecules as novel anti-inflammatory agents to treat inflammatory diseases are discussed.
Journal ArticleDOI

The interplay between vitamin D and viral infections.

TL;DR: The interplay between viral infections and vitamin D remains an intriguing concept, and the global imprint that vitamin D can have on the immune signature in the context of viral infections is an area of growing interest.
Journal ArticleDOI

Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis

You-yi Li, +120 more
- 01 May 2022 - 
TL;DR: This systematic analysis aims to update RSV-associated acute lower respiratory infection morbidity and mortality at global, regional, and national levels in children aged 0–60 months for 2019, with focus on overall mortality and narrower infant age groups that are targeted by RSV prophylactics in development.